


This Listing of Claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1. (currently amended): Substituted pyrazoline compounds of formula I,



wherein

R¹ represents hydrogen or a linear or branched C₁₋₄-alkyl group,

R², R³, and R⁴ independently of each other represent hydrogen, a linear or branched C₁₋₆-alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R⁸, SH, SR⁸, SOR⁸, SO₂R⁸, NH₂, NHR⁸, NR⁸R⁹, -(C=O)-NH₂, -(C=O)-NHR⁸ or -(C=O)-NR⁸R⁹ whereby R⁸ and R⁹ for each substituent independently represent linear or branched C₁₋₆ alkyl,

R⁵ and R⁶ independently of each other represent a linear or branched C₁₋₆ alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R¹⁰, SH, SR¹⁰, SOR¹⁰, NH₂, NHR¹⁰, NR¹⁰R¹¹, -(C=O)-NH₂, -(C=O)-NHR¹⁰ or -(C=O)-NR¹⁰R¹¹, whereby R¹⁰ and optionally R¹¹ for each substituent independently represent linear or branched C₁₋₆ alkyl;

R⁷ represents hydrogen, a linear or branched C₁₋₆-alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R¹⁰, SH, SR¹⁰, SOR¹⁰, NH₂, NHR¹⁰, NR¹⁰R¹¹, -(C=O)-NH₂, -(C=O)-NHR¹⁰ or -(C=O)-NR¹⁰R¹¹, whereby R¹⁰ and optionally

R¹¹ for each substituent independently represent linear or branched C₁₋₆ alkyl;


with the proviso that

if R¹ and R⁷ are H and R⁵ and R⁶ both represent Cl in the 3- and 4-position of the phenyl ring neither of R², R³ and R⁴ may represent F in the 4-position of the phenyl ring if the other two of R², R³ and R⁴ both represent H;

optionally in a form of one of its stereoisomers or a racemate or in a form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, ~~or a corresponding solvate thereof.~~

2. (original): Compounds according to claim 1, characterized in that at least one of R², R³ or R⁴ represents hydrogen, while at least one of R², R³ or R⁴ is different from hydrogen.
3. (previously presented): Compounds according to claim 1, characterized in that R⁷ represents hydrogen.
4. (previously presented): Compounds according to claim 1, characterized in that R², R³ and R⁴ independently of each other represent hydrogen, a linear or branched C₁₋₆-alkyl group, a halogen atom, or CF₃.
5. (previously presented): Compounds according to claim 1, characterized in that R⁵ and R⁶ independently of each other represent a linear or branched C₁₋₆-alkyl group, a halogen atom, or CF₃.
6. (previously presented): Compounds according to claim 1, characterized in that R² represents a chlorine atom in the 4-position of the phenyl ring, while R³ and R⁴ represent hydrogen.

7. (previously presented): Compounds according to claim 1, characterized in that R⁵ and R⁶ each represent chlorine atoms in the 2- and 4-position of the phenyl ring, while R⁷ represents hydrogen.
8. (previously presented): Compounds according to claim 1, characterized in that R¹ represents hydrogen, methyl or ethyl.
9. (currently amended): Compounds of formula II according to claim 1




wherein

R¹ represents hydrogen or a linear or branched C₁₋₄-alkyl group,

R¹² or R¹³ independently of each other represent a linear or branched C₁₋₆-alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, SH, NH₂, hydrogen, methyl, ethyl, F, Cl, Br or CF₃,

R¹⁴ or R¹⁵ independently of each other represent a linear or branched C₁₋₆-alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, SH, NH₂, methyl, ethyl, F, Cl, Br or CF₃,

and at least one substituted pyrazoline compound of general formula X



X

wherein

R¹⁶ represents an optionally at least mono-substituted phenyl group,

R¹⁷ represents an optionally at least mono-substituted phenyl group,

R¹⁸ represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an -NR¹⁹R²⁰-moiety,

R¹⁹ and R²⁰, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system or bonded via a linear or branched alkylene group, an -SO₂-R²¹-moiety, or an -NR²²R²³-moiety, with the proviso that R¹⁹ and R²⁰ do not identically represent hydrogen,

R²¹ represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted

aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system or bonded via a linear or branched alkylene group,

R²² and R²³, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system or bonded via a linear or branched alkylene group,


optionally in a form of one of its stereoisomers or a racemate or in a form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, ~~or a corresponding solvate thereof.~~

Claims 17-39 (canceled)

40. (previously presented): Process for the manufacture of substituted pyrazoline compounds of formula I or II, wherein R¹ is hydrogen, according to claim 1, characterized in that at least one benzaldehyde compound of formula III


optionally in a form of one of its stereoisomers or a racemate or in a form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, ~~or a corresponding solvate thereof.~~

10. (previously presented): Compounds according to claim 9 characterized in that R¹² and R¹³ independently of each other represent hydrogen, a linear or branched C₁₋₆-alkyl group, a halogen atom, or CF₃.
11. (previously presented): Compounds according to claim 9, characterized in that R¹⁴ and R¹⁵ independently of each other represent a linear or branched C₁₋₆-alkyl group, a halogen atom, or CF₃.
12. (previously presented): Compounds according to claim 9, characterized in that R¹³ represents Cl and R¹² represents hydrogen.
13. (previously presented): Compounds according to claim 9, characterized in that R¹⁴ and R¹⁵ each represent Cl.
14. (previously presented): Compounds according to claim 9, characterized in that R¹ represents hydrogen, methyl or ethyl.
15. (currently amended): A compound according to claim 1 which is:
5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-carboxylic acid,
optionally in the form of a corresponding N-oxide, a corresponding salt ~~or a corresponding solvate.~~
16. (withdrawn-currently amended): Combination of compounds comprising at least one substituted pyrazoline compound of formula I of claim 1




(III)

wherein R^2 , R^3 and R^4 have the meaning according to claim 1, is reacted with a pyruvate compound of formula (IV)




(IV),

wherein G represents an OR group with R being a branched or unbranched C_{1-6} alkyl radical or G represents an $\text{O}^- \text{K}$ group with K being a cation, to yield a compound of formula (V)




(V)

which is optionally isolated or optionally purified, and which is reacted with an optionally substituted phenyl hydrazine of formula (VI)



(VI)


or a corresponding salt thereof, wherein R^5 , R^6 and R^7 have the meaning according to claim 1, under inert atmosphere, to yield a compound of formula (VII)



(VII)

wherein R^2 , R^3 , R^4 , R^5 , R^6 and R^7 have the meaning as given above, which is optionally isolated or optionally purified, and optionally esterified to an alkyl-ester if in the substituted pyrazoline compound of formula I according to claim 1 R^1 is a linear or branched C_{1-4} -alkyl group.

41. (withdrawn): Medicament comprising at least one substituted pyrazoline compound of formula I or II according to claim 1, and optionally one or more pharmaceutically acceptable excipients.
42. (withdrawn-currently amended): Medicament comprising at least one substituted pyrazoline compound of general formula I



wherein

R^1 represents hydrogen or a linear or branched C_{1-4} -alkyl group,

R^2 , R^3 and R^4 independently of each other represent hydrogen, a linear or branched C_{1-6} -alkyl group, a linear or branched C_{1-6} -alkoxy group, a halogen atom, CH_2F , CHF_2 , CF_3 , CN , OH , NO_2 , $-(C=O)-R^8$, SH , SR^8 , SOR^8 , SO_2R^8 , NH_2 , NHR^8 , NR^8R^9 , $-(C=O)-NH_2$, $-(C=O)-NHR^8$ or $-(C=O)-NR^8R^9$ whereby R^8 and R^9 for each substituent independently represent linear or branched C_{1-6} alkyl,

R^5 , R^6 and R^7 independently of each other represent hydrogen, a linear or branched C_{1-6} -alkyl group, a linear or branched C_{1-6} -alkoxy group, a halogen atom, CH_2F , CHF_2 , CF_3 , CN , OH , NO_2 , $-(C=O)-R^{10}$, SH , SR^{10} , SOR^{10} , NH_2 , NHR^{10} , $NR^{10}R^{11}$, $-(C=O)-NH_2$, $-(C=O)-NHR^{10}$ or $-(C=O)-NR^{10}R^{11}$, whereby R^{10} and optionally R^{11} for each substituent independently represent linear or branched C_{1-6} alkyl;

optionally in form of one of its stereoisomers or a racemate or in a form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, ~~or a corresponding solvate thereof;~~
and optionally one or more pharmaceutically acceptable excipients.

Claims 43-64 (canceled)

65. (withdrawn): A method for the regulation of triglyceride levels in the blood plasma or for the prophylaxis or treatment of disorders of the central nervous system, or of food intake disorders, the method comprising administering one or more substituted pyrazoline compounds of claim 1 and optionally one or more pharmaceutically acceptable excipients.

Claims 66-86 (canceled)